Ethnic differences in drug metabolism and toxicity from chemotherapy

Bibliography

• Wilkinson GR. Drug metabolism and variability among patients in drug response. N Engl J Med 2005;352(21):2211-21
   PubMed Web of Science ®Google Scholar
• Evans WE, McLeod HL. Pharmacogenomics–drug disposition, drug targets, and side effects. N Engl J Med 2003;348(6):538-49
   PubMed Web of Science ®Google Scholar
• Yasuda SU, Zhang L, Huang SM. The role of ethnicity in variability in response to drugs: focus on clinical pharmacology studies. Clin Pharmacol Ther 2008;84(3):417-23
   PubMed Web of Science ®Google Scholar
• Cropp CD, Yee SW, Giacomini KM. Genetic variation in drug transporters in ethnic populations. Clin Pharmacol Ther 2008;84(3):412-6
   PubMed Web of Science ®Google Scholar
• Myrand SP, Sekiguchi K, Man MZ, et al. Pharmacokinetics/genotype associations for major cytochrome P450 enzymes in native and first- and third-generation Japanese populations: comparison with Korean, Chinese, and Caucasian populations. Clin Pharmacol Ther 2008;84(3):347-61
   PubMed Web of Science ®Google Scholar
• Huang N, Agrawal V, Giacomini KM, Miller WL. Genetics of P450 oxidoreductase: sequence variation in 842 individuals of four ethnicities and activities of 15 missense mutations. Proc Natl Acad Sci USA 2008;105(5):1733-8
   PubMed Web of Science ®Google Scholar
• Chen ML. Ethnic or racial differences revisited: impact of dosage regimen and dosage form on pharmacokinetics and pharmacodynamics. Clin Pharmacokinet 2006;45(10):957-64
   PubMed Web of Science ®Google Scholar
• Ma B, Yeo W, Hui P, et al. Acute toxicity of adjuvant doxorubicin and cyclophosphamide for early breast cancer – a retrospective review of Chinese patients and comparison with an historic Western series. Radiother Oncol 2002;62(2):185-9
   PubMed Web of Science ®Google Scholar
• Bhopal R. Glossary of terms relating to ethnicity and race: for reflection and debate. J Epidemiol Community Health 2004;58(6):441-5
   PubMed Web of Science ®Google Scholar
• Ng PC, Zhao Q, Levy S, et al. Individual genomes instead of race for personalized medicine. Clin Pharmacol Ther 2008;84(3):306-9
   PubMed Web of Science ®Google Scholar
• Suarez-Kurtz G. The implications of population admixture in race-based drug prescription. Clin Pharmacol Ther 2008;83(3):399-400; author reply
   PubMed Web of Science ®Google Scholar
• Available from: http://www.fda.gov/cber/gdlns/racethclin.pdf
   Google Scholar
• Available from: www.imm.ki.se/CYPalleles
   Google Scholar
• Robert J, Morvan VL, Smith D, et al. Predicting drug response and toxicity based on gene polymorphisms. Crit Rev Oncol Hematol 2005;54(3):171-96
   PubMed Web of Science ®Google Scholar
• Chowbay B, Zhou S, Lee EJ. An interethnic comparison of polymorphisms of the genes encoding drug-metabolizing enzymes and drug transporters: experience in Singapore. Drug Metab Rev 2005;37(2):327-78
   PubMed Web of Science ®Google Scholar
• Inoue K, Asao T, Shimada T. Ethnic-related differences in the frequency distribution of genetic polymorphisms in the CYP1A1 and CYP1B1 genes in Japanese and Caucasian populations. Xenobiotica 2000;30(3):285-95
   PubMed Web of Science ®Google Scholar
• Garte S. The role of ethnicity in cancer susceptibility gene polymorphisms: the example of CYP1A1. Carcinogenesis 1998;19(8):1329-32
   PubMed Web of Science ®Google Scholar
• Rosemary J, Adithan C. The pharmacogenetics of CYP2C9 and CYP2C19: ethnic variation and clinical significance. Curr Clin Pharmacol 2007;2(1):93-109
   PubMedGoogle Scholar
• Bosch TM, Meijerman I, Beijnen JH, Schellens JH. Genetic polymorphisms of drug-metabolising enzymes and drug transporters in the chemotherapeutic treatment of cancer. Clin Pharmacokinet 2006;45(3):253-85
   PubMed Web of Science ®Google Scholar
• Dai D, Zeldin DC, Blaisdell JA, et al. Polymorphisms in human CYP2C8 decrease metabolism of the anticancer drug paclitaxel and arachidonic acid. Pharmacogenetics 2001;11(7):597-607
   PubMedGoogle Scholar
• Garcia-Martin E, Martinez C, Ladero JM, Agundez JA. Interethnic and intraethnic variability of CYP2C8 and CYP2C9 polymorphisms in healthy individuals. Mol Diagn Ther 2006;10(1):29-40
   PubMed Web of Science ®Google Scholar
• Klose TS, Blaisdell JA, Goldstein JA. Gene structure of CYP2C8 and extrahepatic distribution of the human CYP2Cs. J Biochem Mol Toxicol 1999;13(6):289-95
   PubMed Web of Science ®Google Scholar
• Bahadur N, Leathart JB, Mutch E, et al. CYP2C8 polymorphisms in Caucasians and their relationship with paclitaxel 6alpha-hydroxylase activity in human liver microsomes. Biochem Pharmacol 2002;64(11):1579-89
   PubMed Web of Science ®Google Scholar
• Miners JO, Birkett DJ. Cytochrome P4502C9: an enzyme of major importance in human drug metabolism. Br J Clin Pharmacol 1998;45(6):525-38
   PubMed Web of Science ®Google Scholar
• Desta Z, Zhao X, Shin JG, Flockhart DA. Clinical significance of the cytochrome P450 2C19 genetic polymorphism. Clin Pharmacokinet 2002;41(12):913-58
   PubMed Web of Science ®Google Scholar
• Nakamura K, Goto F, Ray WA, et al. Interethnic differences in genetic polymorphism of debrisoquin and mephenytoin hydroxylation between Japanese and Caucasian populations. Clin Pharmacol Ther 1985;38(4):402-8
   PubMed Web of Science ®Google Scholar
• Jurima M, Inaba T, Kadar D, Kalow W. Genetic polymorphism of mephenytoin p(4′)-hydroxylation: difference between Orientals and Caucasians. Br J Clin Pharmacol 1985;19(4):483-7
   PubMed Web of Science ®Google Scholar
• Bertilsson L, Lou YQ, Du YL, et al. Pronounced differences between native Chinese and Swedish populations in the polymorphic hydroxylations of debrisoquin and S-mephenytoin. Clin Pharmacol Ther 1992;51(4):388-97
   PubMed Web of Science ®Google Scholar
• Sohn DR, Kusaka M, Ishizaki T, et al. Incidence of S-mephenytoin hydroxylation deficiency in a Korean population and the interphenotypic differences in diazepam pharmacokinetics. Clin Pharmacol Ther 1992;52(2):160-9
   PubMed Web of Science ®Google Scholar
• Roh HK, Dahl ML, Tybring G, et al. CYP2C19 genotype and phenotype determined by omeprazole in a Korean population. Pharmacogenetics 1996;6(6):547-51
   PubMedGoogle Scholar
• Goldstein JA. Clinical relevance of genetic polymorphisms in the human CYP2C subfamily. Br J Clin Pharmacol 2001;52(4):349-55
   PubMed Web of Science ®Google Scholar
• Scordo MG, Caputi AP, D'Arrigo C, et al. Allele and genotype frequencies of CYP2C9, CYP2C19 and CYP2D6 in an Italian population. Pharmacol Res 2004;50(2):195-200
   PubMed Web of Science ®Google Scholar
• Gaikovitch EA, Cascorbi I, Mrozikiewicz PM, et al. Polymorphisms of drug-metabolizing enzymes CYP2C9, CYP2C19, CYP2D6, CYP1A1, NAT2 and of P-glycoprotein in a Russian population. Eur J Clin Pharmacol 2003;59(4):303-12
   PubMed Web of Science ®Google Scholar
• Lee SS, Lee SJ, Gwak J, et al. Comparisons of CYP2C19 genetic polymorphisms between Korean and Vietnamese populations. Ther Drug Monit 2007;29(4):455-9
   PubMed Web of Science ®Google Scholar
• Bernard S, Neville KA, Nguyen AT, Flockhart DA. Interethnic differences in genetic polymorphisms of CYP2D6 in the U.S. population: clinical implications. Oncologist 2006;11(2):126-35
   PubMed Web of Science ®Google Scholar
• Thompson EE, Kuttab-Boulos H, Yang L, et al. Sequence diversity and haplotype structure at the human CYP3A cluster. Pharmacogenomics J 2006;6(2):105-14
   PubMed Web of Science ®Google Scholar
• Hu YF, He J, Chen GL, et al. CYP3A5*3 and CYP3A4*18 single nucleotide polymorphisms in a Chinese population. Clin Chim Acta 2005;353(1-2):187-92
   PubMed Web of Science ®Google Scholar
• Roy JN, Lajoie J, Zijenah LS, et al. CYP3A5 genetic polymorphisms in different ethnic populations. Drug Metab Dispos 2005;33(7):884-7
   PubMed Web of Science ®Google Scholar
• Daly AK. Significance of the minor cytochrome P450 3A isoforms. Clin Pharmacokinet 2006;45(1):13-31
   PubMed Web of Science ®Google Scholar
• Wei X, Elizondo G, Sapone A, et al. Characterization of the human dihydropyrimidine dehydrogenase gene. Genomics 1998;51(3):391-400
   PubMed Web of Science ®Google Scholar
• van Kuilenburg AB. Dihydropyrimidine dehydrogenase and the efficacy and toxicity of 5-fluorouracil. Eur J Cancer 2004;40(7):939-50
   PubMed Web of Science ®Google Scholar
• Hsiao HH, Yang MY, Chang JG, et al. Dihydropyrimidine dehydrogenase pharmacogenetics in the Taiwanese population. Cancer Chemother Pharmacol 2004;53(5):445-51
   PubMed Web of Science ®Google Scholar
• Maekawa K, Saeki M, Saito Y, et al. Genetic variations and haplotype structures of the DPYD gene encoding dihydropyrimidine dehydrogenase in Japanese and their ethnic differences. J Hum Genet 2007;52(10):804-19
   PubMed Web of Science ®Google Scholar
• Garat A, Cauffiez C, Renault N, et al. Characterisation of novel defective thiopurine S-methyltransferase allelic variants. Biochem Pharmacol 2008;76(3):404-15
   PubMed Web of Science ®Google Scholar
• Collie-Duguid ES, Pritchard SC, Powrie RH, et al. The frequency and distribution of thiopurine methyltransferase alleles in Caucasian and Asian populations. Pharmacogenetics 1999;9(1):37-42
   PubMedGoogle Scholar
• Coulthard SA, Hall AG. Recent advances in the pharmacogenomics of thiopurine methyltransferase. Pharmacogenomics J 2001;1(4):254-61
   PubMedGoogle Scholar
• Hayes JD, Flanagan JU, Jowsey IR. Glutathione transferases. Annu Rev Pharmacol Toxicol 2005;45:51-88
   PubMed Web of Science ®Google Scholar
• Rebbeck TR. Molecular epidemiology of the human glutathione S-transferase genotypes GSTM1 and GSTT1 in cancer susceptibility. Cancer Epidemiol Biomarkers Prev 1997;6(9):733-43
   PubMed Web of Science ®Google Scholar
• McIlwain CC, Townsend DM, Tew KD. Glutathione S-transferase polymorphisms: cancer incidence and therapy. Oncogene 2006;25(11):1639-48
   PubMed Web of Science ®Google Scholar
• Zhong SL, Zhou SF, Chen X, et al. Relationship between genotype and enzyme activity of glutathione S-transferases M1 and P1 in Chinese. Eur J Pharm Sci 2006;28(1-2):77-85
   PubMed Web of Science ®Google Scholar
• Nelson HH, Wiencke JK, Christiani DC, et al. Ethnic differences in the prevalence of the homozygous deleted genotype of glutathione S-transferase theta. Carcinogenesis 1995;16(5):1243-5
   PubMed Web of Science ®Google Scholar
• Tran A, Jullien V, Alexandre J, et al. Pharmacokinetics and toxicity of docetaxel: role of CYP3A, MDR1, and GST polymorphisms. Clin Pharmacol Ther 2006;79(6):570-80
   PubMed Web of Science ®Google Scholar
• Kuhne A, Sezer O, Heider U, et al. Population pharmacokinetics of melphalan and glutathione S-transferase polymorphisms in relation to side effects. Clin Pharmacol Ther 2008;83(5):749-57
   PubMed Web of Science ®Google Scholar
• Mackenzie PI, Miners JO, McKinnon RA. Polymorphisms in UDP glucuronosyltransferase genes: functional consequences and clinical relevance. Clin Chem Lab Med 2000;38(9):889-92
   PubMed Web of Science ®Google Scholar
• Beutler E, Gelbart T, Demina A. Racial variability in the UDP-glucuronosyltransferase 1 (UGT1A1) promoter: a balanced polymorphism for regulation of bilirubin metabolism? Proc Natl Acad Sci USA 1998;95(14):8170-4
   PubMed Web of Science ®Google Scholar
• Bhasker CR, McKinnon W, Stone A, et al. Genetic polymorphism of UDP-glucuronosyltransferase 2B7 (UGT2B7) at amino acid 268: ethnic diversity of alleles and potential clinical significance. Pharmacogenetics 2000;10(8):679-85
   PubMedGoogle Scholar
• Jakobsson J, Ekstrom L, Inotsume N, et al. Large differences in testosterone excretion in Korean and Swedish men are strongly associated with a UDP-glucuronosyl transferase 2B17 polymorphism. J Clin Endocrinol Metab 2006;91(2):687-93
   PubMed Web of Science ®Google Scholar
• Ho RH, Choi L, Lee W, et al. Effect of drug transporter genotypes on pravastatin disposition in European- and African-American participants. Pharmacogenet Genomics 2007;17(8):647-56
   PubMed Web of Science ®Google Scholar
• Chen CC, Lu RB, Chen YC, et al. Interaction between the functional polymorphisms of the alcohol-metabolism genes in protection against alcoholism. Am J Hum Genet 1999;65(3):795-807
   PubMed Web of Science ®Google Scholar
• Maring JG, Groen HJ, Wachters FM, et al. Genetic factors influencing pyrimidine-antagonist chemotherapy. Pharmacogenomics J 2005;5(4):226-43
   PubMed Web of Science ®Google Scholar
• Diasio RB, Johnson MR. The role of pharmacogenetics and pharmacogenomics in cancer chemotherapy with 5-fluorouracil. Pharmacology 2000;61(3):199-203
   PubMed Web of Science ®Google Scholar
• Smith NF, Marsh S, Scott-Horton TJ, et al. Variants in the SLCO1B3 gene: interethnic distribution and association with paclitaxel pharmacokinetics. Clin Pharmacol Ther 2007;81(1):76-82
   PubMed Web of Science ®Google Scholar
• Fukuoka M, Yano S, Giaccone G, et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected]. J Clin Oncol 2003;21(12):2237-46
   PubMed Web of Science ®Google Scholar
• Kris MG, Natale RB, Herbst RS, et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA 2003;290(16):2149-58
   PubMed Web of Science ®Google Scholar
• Chang A, Parikh P, Thongprasert S, et al. Gefitinib (IRESSA) in patients of Asian origin with refractory advanced non-small cell lung cancer: subset analysis from the ISEL study. J Thorac Oncol 2006;1(8):847-55
   PubMed Web of Science ®Google Scholar
• Thatcher N, Chang A, Parikh P, et al. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet 2005;366(9496):1527-37
   PubMed Web of Science ®Google Scholar
• Tamura T, Nishiwaki Y, Watanabe K, et al. Evaluation of efficacy and safety of erlotinib as monotherapy for Japanese patients with advanced non-small cell lung cancer (NSCLC); integrated analysis of two Japanese phase II studies. J Thorac Oncol 2007;2(Suppl 4):S742
   Google Scholar
• Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005;353(2):123-32
   PubMed Web of Science ®Google Scholar
• Mok TSZC, Kim S, Wu Y, Perng R. Efficacy and safety of erlotinib in >1200 East/South-East (E/SE) Asian patients (pts) with advanced non-small-cell lung cancer (NSCLC) [abstract 19001]. J Clin Oncol 2008;26(15s):19001
   Google Scholar
• Sekine I, Nokihara H, Yamamoto N, et al. Common arm analysis: one approach to develop the basis for global standardization in clinical trials of non-small cell lung cancer. Lung Cancer 2006;53(2):157-64
   PubMed Web of Science ®Google Scholar
• Yang CH. EGFR tyrosine kinase inhibitors for the treatment of NSCLC in East Asia: present and future. Lung Cancer 2008;60 (Suppl 2):S23-30
   PubMedGoogle Scholar
• Calvo E, Baselga J. Ethnic differences in response to epidermal growth factor receptor tyrosine kinase inhibitors. J Clin Oncol 2006;24(14):2158-63
   PubMed Web of Science ®Google Scholar
• Sequist LV, Bell DW, Lynch TJ, Haber DA. Molecular predictors of response to epidermal growth factor receptor antagonists in non-small-cell lung cancer. J Clin Oncol 2007;25(5):587-95
   PubMed Web of Science ®Google Scholar
• Sekine I, Yamamoto N, Nishio K, Saijo N. Emerging ethnic differences in lung cancer therapy. Br J Cancer 2008;99(11):1757-62
   PubMed Web of Science ®Google Scholar
• Lara PRM, Lenz H, Gordon M, et al. Cisplatin (Cis)/etoposide (VP16) compared to cis/irinotecan (CPT11) in extensive-stage small cell lung cancer (E-SCLC): Pharmacogenomic (PG) and comparative toxicity analysis of JCOG 9511 and SWOG 0124. J Clin Oncol 2007;25(Suppl):390s
   PubMed Web of Science ®Google Scholar
• Millward MJ, Boyer MJ, Lehnert M, et al. Docetaxel and carboplatin is an active regimen in advanced non-small-cell lung cancer: a phase II study in Caucasian and Asian patients. Ann Oncol 2003;14(3):449-54
   PubMed Web of Science ®Google Scholar
• Beith JMGB, Yeo W, Sullivan A, et al. Inter-ethnic differences in the myelotoxicity of adriamycin/cyclophosphamide (AC) for adjuvant breast cancer. Proc Am Soc Clin Oncol 2002;21:252
   Google Scholar
• Ameer B, Weintraub RA. Drug interactions with grapefruit juice. Clin Pharmacokinet 1997;33(2):103-21
   PubMed Web of Science ®Google Scholar
• Malhotra S, Bailey DG, Paine MF, Watkins PB. Seville orange juice-felodipine interaction: comparison with dilute grapefruit juice and involvement of furocoumarins. Clin Pharmacol Ther 2001;69(1):14-23
   PubMed Web of Science ®Google Scholar
• Tsunoda SM, Harris RZ, Christians U, et al. Red wine decreases cyclosporine bioavailability. Clin Pharmacol Ther 2001;70(5):462-7
   PubMed Web of Science ®Google Scholar
• Fontana RJ, Lown KS, Paine MF, et al. Effects of a chargrilled meat diet on expression of CYP3A, CYP1A, and P-glycoprotein levels in healthy volunteers. Gastroenterology 1999;117(1):89-98
   PubMed Web of Science ®Google Scholar
• Pantuck EJ, Pantuck CB, Garland WA, et al. Stimulatory effect of brussels sprouts and cabbage on human drug metabolism. Clin Pharmacol Ther 1979;25(1):88-95
   PubMed Web of Science ®Google Scholar
• de la Maza MP, Hirsch S, Petermann M, et al. Changes in microsomal activity in alcoholism and obesity. Alcohol Clin Exp Res 2000;24(5):605-10
   PubMed Web of Science ®Google Scholar
• Stein CM, Sadeque AJ, Murray JJ, et al. Cyclosporine pharmacokinetics and pharmacodynamics in African American and white subjects. Clin Pharmacol Ther 2001;69(5):317-23
   PubMed Web of Science ®Google Scholar
• Ding X, Lichti K, Kim I, et al. Regulation of constitutive androstane receptor and its target genes by fasting, cAMP, hepatocyte nuclear factor alpha, and the coactivator peroxisome proliferator-activated receptor gamma coactivator-1alpha. J Biol Chem 2006;281(36):26540-51
   PubMed Web of Science ®Google Scholar
• Rashid TJ, Martin U, Clarke H, et al. Factors affecting the absolute bioavailability of nifedipine. Br J Clin Pharmacol 1995;40(1):51-8
   PubMed Web of Science ®Google Scholar
• Slaviero KA, Clarke SJ, Rivory LP. Inflammatory response: an unrecognised source of variability in the pharmacokinetics and pharmacodynamics of cancer chemotherapy. Lancet Oncol 2003;4(4):224-32
   PubMed Web of Science ®Google Scholar
• Robertson GR, Liddle C, Clarke SJ. Inflammation and altered drug clearance in cancer: transcriptional repression of a human CYP3A4 transgene in tumor-bearing mice. Clin Pharmacol Ther 2008;83(6):894-7
   PubMed Web of Science ®Google Scholar
• Miller MA, Cappuccio FP. Ethnicity and inflammatory pathways - implications for vascular disease, vascular risk and therapeutic intervention. Curr Med Chem 2007;14(13):1409-25
   PubMed Web of Science ®Google Scholar
• Kalra L, Rambaran C, Chowienczyk P, et al. Ethnic differences in arterial responses and inflammatory markers in Afro-Caribbean and Caucasian subjects. [see comment]. Arterioscler Thromb Vasc Biol 2005;25(11):2362-7
   PubMed Web of Science ®Google Scholar
• Mwantembe O, Gaillard MC, Barkhuizen M, et al. Ethnic differences in allelic associations of the interleukin-1 gene cluster in South African patients with inflammatory bowel disease (IBD) and in control individuals. Immunogenetics 2001;52(3-4):249-54
   PubMed Web of Science ®Google Scholar
• Szalai AJ, Wu J, Lange EM, et al. Single-nucleotide polymorphisms in the C-reactive protein (CRP) gene promoter that affect transcription factor binding, alter transcriptional activity, and associate with differences in baseline serum CRP level.[see comment]. J Mol Med 2005;83(6):440-7
   PubMed Web of Science ®Google Scholar
• Lakoski SG, Cushman M, Palmas W, et al. The relationship between blood pressure and C-reactive protein in the Multi-Ethnic Study of Atherosclerosis (MESA). J Am Coll Cardiol 2005;46(10):1869-74
   PubMed Web of Science ®Google Scholar
• Yamada H, Dahl ML, Lannfelt L, et al. CYP2D6 and CYP2C19 genotypes in an elderly Swedish population. Eur J Clin Pharmacol 1998;54(6):479-81
   PubMed Web of Science ®Google Scholar
• Liou YH, Lin CT, Wu YJ, Wu LS. The high prevalence of the poor and ultrarapid metabolite alleles of CYP2D6, CYP2C9, CYP2C19, CYP3A4, and CYP3A5 in Taiwanese population. J Hum Genet 2006;51(10):857-63
   PubMed Web of Science ®Google Scholar
• Tamminga WJ, Wemer J, Oosterhuis B, et al. The prevalence of CYP2D6 and CYP2C19 genotypes in a population of healthy Dutch volunteers. Eur J Clin Pharmacol 2001;57(10):717-22
   PubMed Web of Science ®Google Scholar
• Veiga MI, Asimus S, Ferreira PE, et al. Pharmacogenomics of CYP2A6, CYP2B6, CYP2C19, CYP2D6, CYP3A4, CYP3A5 and MDR1 in Vietnam. Eur J Clin Pharmacol 2008 (E-pub ahead of time)
   PubMedGoogle Scholar
• Marsh S, McLeod HL. Cancer pharmacogenetics. Br J Cancer 2004;90(1):8-11
   PubMed Web of Science ®Google Scholar
• Reigner B, Watanabe T, Schuller J, et al. Pharmacokinetics of capecitabine (Xeloda) in Japanese and Caucasian patients with breast cancer. Cancer Chemother Pharmacol 2003;52(3):193-201
   PubMed Web of Science ®Google Scholar
• Shirao K, Matsumura Y, Yamada Y, et al. Phase I study of single-dose oxaliplatin in Japanese patients with malignant tumors. Jpn J Clin Oncol 2006;36(5):295-300
   PubMed Web of Science ®Google Scholar
• Ogawa M, Sampi K, Tsukui T, et al. Pharmacokinetic study of mitoxantrone. Gan To Kagaku Ryoho 1986;13(10):3028-33
   PubMedGoogle Scholar
• Dowsett M, Donaldson K, Tsuboi M, et al. Effects of the aromatase inhibitor anastrozole on serum oestrogens in Japanese and Caucasian women. Cancer Chemother Pharmacol 2000;46(1):35-9
   PubMed Web of Science ®Google Scholar
• Fukushima T, Yamashita T, Goto N, et al. A pharmacokinetic study of idarubicin in Japanese patients with malignant lymphoma: relationship with leukocytopenia and neutropenia. Int J Hematol 2001;74(3):297-302
   PubMed Web of Science ®Google Scholar
• Comets E, Ikeda K, Hoff P, et al. Comparison of the pharmacokinetics of S-1, an oral anticancer agent, in Western and Japanese patients. J Pharmacokinet Pharmacodyn 2003;30(4):257-83
   PubMed Web of Science ®Google Scholar